Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04187872 · ClinicalTrials.gov registry record · Phase 1
LITT and Pembrolizumab in Recurrent Brain Metastasis
A Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04187872 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 10 participants.
The verdict
NCT04187872, a Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).
Interventions
- COMBINATION_PRODUCT LITT + Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04187872
The ClinicalTrials.gov registry entry for NCT04187872 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LITT + Pembrolizumab is the first listed.
NCT04187872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04187872 about?
NCT04187872 is a clinical study titled "LITT and Pembrolizumab in Recurrent Brain Metastasis". This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after...
What is the current status of trial NCT04187872?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-01-10. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04187872?
The interventions under investigation include: LITT + Pembrolizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04187872?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.